As a longtime critic of the FDA, you might expect me to support firing FDA employees—not so! My focus has always been on reducing approval time and costs to speed drugs to patients and increase the number of new drugs. Cutting staff is more likely to slow approvals and raise costs.

To be fair, we’re talking about the firing of some 200 probationary employees from a total of some 20,000. Unusual but not earth shaking. But the firings are indiscriminate, and as I explain below, the FDA is a peculiar target for cost-cutting because user fees under PDUFA cover a significant share of the FDA’s budget so its workers are among the cheapest federal employees. So what is the point? Shock and awe in advance of bigger reforms for the FDA? Perhaps. Regardless, I think we should keep in mind the big picture on staff and

Keep reading this article on Marginal Revolution.